Clinical decision support, not a substitute for clinical judgment. Verify allergies, drug interactions, and renal/hepatic dose adjustments before administration. [Replace this sentence with protocol-appropriate caveats about evidence quality, regulatory grade, or guideline limitations.]
Interactive Visualizer
How Modern CKD Therapies Reduce Kidney Failure Risk
Modern CKD therapies can significantly slow kidney disease progression and reduce the
risk of kidney failure. Explore how kidney-protective treatments may help preserve
kidney function over time.
Enter your kidney numbers above
Once you calculate your 5-year kidney failure risk using the heat map tool above,
this visualizer will show how modern therapies could lower that risk.
Risk reduction visualizer not applicable
The Kidney Failure Risk Equation is validated for CKD stages G3–G5 (eGFR < 60).
Because your eGFR is in the normal-to-mildly-decreased range, a meaningful baseline risk
cannot be calculated here. This is generally reassuring — discuss prevention strategies
with your nephrology team.
Estimated 5-Year Risk
0.0%
—
Current KFRE 5-Year Risk
—
Estimated Reduced Risk
—
Risk Reduction
—
Kidney Protection Active
The benefits of these therapies can add up.
Each therapy shown above protects your kidneys in a different way. Many patients
benefit from combining several approaches — your nephrology team can help decide
which combination is right for you.
Potential Slowing of Kidney Disease Progression
Illustrative kidney function (eGFR) over time. Dialysis threshold shown for reference.
◷Select a therapy above to visualize potential delay in dialysis timeline
Risk reduction illustrations are educational estimates only and are not individualized
predictions. Treatment decisions should always be made with your healthcare provider.
Risk reduction estimates are aligned with Dr. Naveed Tangri's published
patient education tool (KFRE author) and supported by landmark CKD trials:
SPRINT and MDRD for blood pressure control; RENAAL, IDNT, and Cochrane meta-analyses
for ACEi/ARB therapy; DAPA-CKD, EMPA-KIDNEY, and the SMART-C meta-analysis for
SGLT2 inhibitors; FIDELIO-DKD and FIDELITY pooled analysis for finerenone in T2DM.
Each therapy is shown independently — combined benefits in clinical practice can be
additive but cannot be quantified precisely from current trial data.
